{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:24:15Z","timestamp":1791973455924,"version":"4.4.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,7,7]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>A pooled analysis of 2 daratumumab trials showed no new safety signals, an overall response rate of 31%, and deep and durable responses. Median overall survival was 20.1 months; benefit was also shown in patients who achieved minimal response\/stable disease.<\/jats:p>","DOI":"10.1182\/blood-2016-03-705210","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T03:55:04Z","timestamp":1464062104000},"page":"37-44","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":366,"title":["Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma"],"prefix":"10.1182","volume":"128","author":[{"given":"Saad Z.","family":"Usmani","sequence":"first","affiliation":[{"name":"Levine Cancer Institute\/Carolinas HealthCare System, Charlotte, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan M.","family":"Weiss","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Plesner","sequence":"additional","affiliation":[{"name":"Vejle Hospital and University of Southern Denmark, Vejle, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Center\u2013University of Calgary, Calgary, AB, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Belch","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute, Edmonton, AB, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk M.","family":"Lokhorst","sequence":"additional","affiliation":[{"name":"Department of Hematology, VU Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Kate","family":"Sasser","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Axel","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaibao","family":"Feng","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Raritan, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa M.","family":"Uhlar","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Wang","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Khan","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Raritan, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahamtan","family":"Ahmadi","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hareth","family":"Nahi","sequence":"additional","affiliation":[{"name":"Karolinska Institute, Division of Hematology, Department of Medicine, Karolinska University Hospital at Huddinge, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111904244574200_B1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies.","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111904244574200_B2","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/leu.2008.402","article-title":"Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).","volume":"23","author":"Kastritis","year":"2009","journal-title":"Leukemia"},{"key":"2019111904244574200_B3","author":"Usmani"},{"issue":"3","key":"2019111904244574200_B4","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"issue":"2","key":"2019111904244574200_B5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"2019111904244574200_B6","author":"Lammerts van Bueren"},{"issue":"1","key":"2019111904244574200_B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: a (r)evolutionary story of enzymes and receptors.","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk Res"},{"issue":"4","key":"2019111904244574200_B8","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","article-title":"Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.","volume":"121","author":"Lin","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"2019111904244574200_B9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.leukres.2003.09.015","article-title":"Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.","volume":"28","author":"Santonocito","year":"2004","journal-title":"Leuk Res"},{"key":"2019111904244574200_B10","article-title":"Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma [published online ahead of print May 24, 2016].","author":"Krejcik","journal-title":"Blood"},{"issue":"13","key":"2019111904244574200_B11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma.","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"10027","key":"2019111904244574200_B12","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"2019111904244574200_B13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-015-0536-1","article-title":"Daratumumab: First Global Approval.","volume":"76","author":"McKeage","year":"2016","journal-title":"Drugs"},{"issue":"6 Pt 2","key":"2019111904244574200_B14","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing.","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"issue":"6 Pt 2","key":"2019111904244574200_B15","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/trf.13150","article-title":"When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy.","volume":"55","author":"Oostendorp","year":"2015","journal-title":"Transfusion"},{"issue":"26","key":"2019111904244574200_B16","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma.","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111904244574200_B17","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"14","key":"2019111904244574200_B18","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2019111904244574200_B19","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2008-12-196238","article-title":"Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.","volume":"114","author":"Richardson","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111904244574200_B20","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.3109\/10428194.2012.661175","article-title":"Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed\/refractory multiple myeloma.","volume":"53","author":"Wolf","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2019111904244574200_B21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"issue":"Supplement 5","key":"2019111904244574200_B22","article-title":"Carfilzomib (K) vs low-dose corticosteroids and optional cyclophosphamide (Cy) in patients (pts) with relapsed and refractroy multiple myeloma (RRMM): Results from a phase 3 study (FOCUS) [abstract].","volume":"25","author":"Ludwig","year":"2014","journal-title":"Ann Oncol"},{"issue":"11","key":"2019111904244574200_B23","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"21","key":"2019111904244574200_B24","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer.","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111904244574200_B25","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111904244574200_B26","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/1\/37\/1395531\/37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/1\/37\/1395531\/37.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T09:24:56Z","timestamp":1574155496000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/1\/37\/35360\/Clinical-efficacy-of-daratumumab-monotherapy-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-03-705210","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,7]]}}}